← Back to Analyst Consensus 
MANE Buy
Veradermics, Inc
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 3 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 55% |
| Oct 19, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Oct 19, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 16, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 15, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 15, 2026 | B. Riley Securities | initiate | — → Buy | — | 55% |
| Jul 7, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Jun 16, 2026 | LifeSci Capital | initiate | — → Outperform | — | 57% |
| Jun 2, 2026 | Needham | initiate | — → Buy | — | 50% |
| May 18, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Mar 2, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 2, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Mar 2, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Mar 2, 2026 | Jefferies | initiate | — → Buy | — | 52% |
Price Target Trend
Jun 17, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days